Novel heterocyclic thyromimetics. Part 2

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 14, 2007, Pages 3992-3996

  Haning, Helmut ^a   Mueller, Ulrich ^a   Schmidt, Gunter ^a   Schmeck, Carsten ^a   Voehringer, Verena ^a   Kretschmer, Axel ^a   Bischoff, Hilmar ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Benzofuranes; Thiazinane 2,4 dione; Thyromimetics

Indexed keywords

3,5 DIBROMO 3' (2,3 DIHYDRO 3 OXO 6 PYRIDAZINYLMETHYL)THYRONINE; BENZOFURAN DERIVATIVE; HETEROCYCLIC COMPOUND; KB 141; THYROID HORMONE RECEPTOR; THYROMIMETIC AGENT; UNCLASSIFIED DRUG;

AGONIST; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

HETEROCYCLIC COMPOUNDS; MOLECULAR MIMICRY; STRUCTURE-ACTIVITY RELATIONSHIP; THYROID HORMONES;

EID: 34250311979     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.04.085     Document Type: Article

References (28)

1. Haning H., Woltering M., Mueller U., Schmidt G., Schmeck C., Voehringer V., Kretschmer A., and Pernerstorfer J. Bioorg. Med. Chem. Lett. 15 (2005) 1835
2. Yoshihara H.A., Apriletti J.W., Baxter J.D., and Scanlan T.S. J. Med. Chem. 46 (2003) 3152
3. Hangeland J.J., Doweyko A.M., Dejneka T., Friends T.J., Devasthale P., Mellström K., Sandberg J., Grynfarb M., Sack J.S., Einspahr H., Färnegårdh M., Husman B., Ljunggren J., Koehler K., Sheppard C., Malm J., and Ryono D.E. Bioorg. Med. Chem. Lett. 14 (2004) 3549
4. Li Y.L., Koehler K.F., Mellström K., Garg N., Garcia Collazo A.M., Färnegard M., Gynfarb M., Husmann B., Sandberg J., and Malm J. Bioorg. Med. Chem. Lett. 16 (2006) 884
5. Hangeland J.J., Friends T.J., Doweyko A.M., Mellström K., Sandberg J., Grynfarb M., and Ryono D.E. Bioorg. Med. Chem. Lett. 15 (2005) 4579
6. Dow R.L., Schneider S.R., Paight E.S., Hank R.F., Chiang P., Cornelius P., Lee E., Newsome W.P., Swick A.G., Spitzer J., Hargrove D.M., Patterson T.A., Pandit J., Chrunyk B.A., LeMotte P.K., Danley D.E., Rosner M.H., Ammirati M.J., Simons S.P., Schulte G.K., Tate B.F., and DaSilva-Jardine P. Bioorg. Med. Chem. Lett. 13 (2003) 379
7. Grover G.J., Mellström K., Ye L., Malm J., Li Y.L., Bladh L.G., Sleph P.G., Smith M.A., George R., Vennström B., Mookhtiar K., Horvath R., Speelman J., Egan D., and Baxter J. PNAS 100 (2003) 10067
8. Ye l., Li Y.-L., Mellström K., Mellin C., Bladh L.-G., Koehler K., Garg N., Garcia Collazo A.M., Litten C., Husman B., Persson K., Ljunggren J., Grover G., Sleph P.G., George R., and Malm J. J. Med. Chem. 46 (2003) 1580
9. Chiellini G., Apriletti J.W., Yoshihara H.A., Baxter J.D., Ribeiro R.CJ., and Scanlan T.S. Chem. Biol. 5 (1998) 299
10. Wagner R.L., Huber B.R., Shiau A.K., Kelly A., Cunha Lima S.T., Scanlan T.S., Apriletti J.W., Baxter J.D., West B.L., and Fletterick R.J. Mol. Endocrinol. 15 (2005) 398
11. Baxter J.D., Dillmann W.H., West B.L., Huber R., Furlow J.D., Fletterick R.J., Webb P., Apriletti J.W., and Scanlan T.S. J. Steroid Biochem. Mol. Biol. 76 (2001) 31
12. Stephan Z.F., Yurachek E.C., Sharif R., Wasvary J.M., Stele R.E., and Howes C. Biochem. Pharmacol. 43 (1992) 1969
13. Underwood A.H., Emmett J.C., Ellis D., Flynn S.B., Leeson P.D., Benson G.M., Novelli R., Pearce N.J., and Shah V.P. Nature 324 (1986) 425
14. Ichikawa K., Miyamoto T., Kakizawa T., Suzuki S., Kaneko A., Mori J., Hara M., Kumagai M., Takeda T., and Hashizume K. J. Endocrinol. 165 (2000) 391
15. Garcia Collazo A.M., Koehler K.F., Garg N., Färnegardh M., Husman B., Ye L., Lunggren J., Mellström K., Sandberg J., Gynfarb M., Ahola H., and Malm J. Bioorg. Med. Chem. Lett. 16 (2006) 1240
16. Yokoyama N., Walker G.N., Main A.J., Stanton J.L., Morrissey M.M., Boehm C., Engle A., Neubert A.D., Wasvary J.M., Stephan Z.F., and Steele R.E. J. Med. Chem. 38 (1995) 695
17. Höfer A., and Cahnmann H.J. J. Med. Chem. 7 (1964) 326
18. Pages R.A., and Burger A. J. Med. Chem. 10 (1967) 435
19. D'Sa B.A., Kisanga P., and Verkade J.G. Synlett 5 (2001) 670
20. Fall Y., Santana L., Teijeira M., and Uriarte E. Heterocycles 41 (1995) 647
21. Ceccarelli S., De Vellis P., Scuri R., Zanarella S., and Brufani M. J. Heterocycl. Chem. 30 (1993) 679
22. Hickey D., Leeson P.D., Novelli R., Shah V.P., Burpitt B.E., Crawford L.P., Davies B.J., Mitchell M.M.B., and Pancholi K.D. J. Chem. Soc., Perkin Trans. 1 12 (1988) 3103
23. Li, Y. L.; Liu, Y.; Hedfors, A.; Malm, J.; Mellin, C.; Zhang, M., WO9900353; Chem. Abstr. 1999, 130, 110054.
24. Ebisawa M., Inoue N., Fukusawa H., Sotome T., and Kagechika H. Chem. Pharm. Bull. 47 (1999) 1348
25. Hashimoto A., Shi Y., Drake K., and Koh J.T. Bioorg. Med. Chem. 13 (2005) 3627
26. Ocasio C.A., and Scanlan T.S. Chem. Biol. 1 (2006) 585
27. NMRI mice (8-10 animals per group) were orally treated once daily by gavage (vehicle: solutol/ethanol/water 10:10:80) with doses of 0.1, 0.3, 1.0 and 3.0 mg/kg with the ethyl ester of compound 21 over a period of 7 days. At the end of the study blood was retroorbitally collected and serum cholesterol and triglyceride concentration levels were enzymatically determined using commercially available test kits (Boehringer Mannheim, Germany) and an autoanalyzer (EPOS 5060, Eppendorf Gerätebau, Hamburg, Germany). Serum cholesterol reductions of 32%, 34%, 39% and 41% versus control were determined.
28. C57BL/6J mice (10-12 animals per group) were orally treated once daily by gavage (vehicle: solutol/ethanol/water 10:10:80) with doses of 0.1, 0.3 and 3.0 mg/kg with the ethyl ester of compound 21 over a period of 11 days. At the end of the study heart rate was determined using a computerized non-invasive tail cuff system (TSE Systems GmbH, Bad Homburg, Germany). Animals were sacrificed and heart weight was determined. Increases in heart weight of 12%, 17% and 27% were determined, respectively.